12:00 AM
 | 
Sep 15, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Trastuzumab-DM1: Phase II data

Interim data from 30 evaluable patients in an open-label Phase II trial evaluating IV trastuzumab-DM1 showed that 9 patients had objective responses (OR) as determined by an Independent Review Facility, surpassing the criterion of 5 OR for study continuation. An assessment by investigator of the evaluable patients...

Read the full 215 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >